Considerations on the Management of Macular Neovascularization in Patients with Geographic Atrophy Enrolled in Clinical Trials. Kaiser P, et al. Retina Today. 2022; March supplement:1-14.
ViewPublications & Presentations
Explore Iveric Bio’s pipeline, published articles, posters and presentations in geographic atrophy and beyond.
OUR PIPELINE
With a diverse portfolio of therapeutic candidates at different stages of development, Iveric Bio is focused on bringing innovative treatments for retinal diseases to those who need them most. Our pipeline includes our lead product candidate, avacincaptad pegol, which is being developed as a treatment for geographic atrophy (GA). Other candidates include IC-500 for GA, and AAV gene therapies for other retinal diseases.
EXPLORE OUR PIPELINEPUBLISHED ARTICLES
Read published articles to learn more about the results of our clinical research on geographic atrophy and beyond.
POSTERS & PRESENTATIONS
View posters and presentations to learn more about our clinical research on geographic atrophy and beyond.
PRESENTATION
Khanani et al. The Efficacy of Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results. Retina Society 2022
view
PRESENTATION
Kaiser et al. Safety of Intravitreal Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results. Retina Society 2022
view
PRESENTATION
Mohammed Rafieetary. Avacincaptad Pegol for Geographic Atrophy. A Review of the GATHER1 and GATHER2 Clinical Trials. AAOpt 2022
view
PRESENTATION
Khanani et al. GATHER2 Pivotal Phase 3 Study Results: Efficacy of Intravitreal Avacincaptad Pegol in Geographic Atrophy. AAO 2022
view
PRESENTATION
Heier et al. GATHER2 Pivotal Phase 3 Study Results: Safety of Intravitreal Avacincaptad Pegol in Geographic Atrophy. AAO 2022
view
PRESENTATION
Lally et al. Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study. ASRS 2022
view